Lang Matthew 4
4 · Lyell Immunopharma, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Lang Matthew
Chief Business Officer
Transactions
- Award
Common Stock
2024-02-09+50,000→ 50,000 total - Award
Option (right to buy)
2024-02-09+500,000→ 500,000 totalExercise: $1.80Exp: 2034-02-08→ Common Stock (500,000 underlying)
Footnotes (2)
- [F1]The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.